GLPwatch
Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.
Health Sci Rep · 2024
Last updated 2026-05-28Retatrutide is a new type of drug being studied for weight loss in people with obesity or overweight. In clinical trials, it showed dose-dependent weight reduction with a generally safe side effect profile. The drug works by targeting three pathways and is expected to lead to significant weight loss, though the exact amount of weight lost is not provided in the abstract.
AI summary of the abstract below.
| Journal | Health Sci Rep, 2024 |
|---|---|
| Citations | 6 |
| Relative citation ratio | 1.23 |
| NIH percentile | 57 |
| Molecules | retatrutide |
| Conditions studied | Obesity |
Abstract
BACKGROUND AND AIMS: Overweight and obesity have become global health challenges with increasing prevalence. Several drugs have received Food and Drug Administration approval for nonsyndromic obesity treatment, but most have limitations, including gastrointestinal side effects and limited weight loss efficacy.
BODY: Retatrutide, a novel incretin mimetic agent, has shown promise in clinical trials for significant weight reduction. It has demonstrated dosage-dependent pharmacokinetics with favorable safety profiles. The primary focus of this paper is to explore retatrutide and critically assess its clinical trials to justify its use and feasibility while highlighting its shortcomings. This paper also delves into the subject of obesity and its health manifestations.
CONCLUSION: It is expected that the use of retatrutide, a triple agonist, will result in significant weight loss among individuals who are obese or overweight.
Verbatim abstract via PubMed 38323122 ↗
Related research
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
- The power of three: Retatrutide's role in modern obesity and diabetes therapy.
- Retatrutide showing promise in obesity (and type 2 diabetes).
- Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.